All In Biotech

Drug Trial Radar · NCT01628731

Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease

Phase III Study of Furosemide Continuous Infusion Versus Ethacrynic Acid Continuous Infusion in Children Undergoing Cardiac Surgery: Randomized Double Blind Controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

74

Actual

Start

Oct 2012

Primary completion

Jul 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to verify if ethacrynic acid continuous infusion is superior to furosemide continuous infusion in total urine output production during the first 24 post operative hours.

Conditions

  • Fluid Overload

Interventions

  • furosemideDrug

    furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours

  • ethacrynic acidDrug

    ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean total urine output production in the first post-operative dayTime frame: first 24 hours after Intensive Care Unit admission

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bambino Gesù Hospital

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.